This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dunn, B. K. Articles by Ford, L. G. Search for Related Content PubMed PubMed Citation Articles by Dunn, B. K. Articles by Ford, L. G. Social Bookmarking                            What's this?

Prevention of Hormone-Related Cancers: Breast Cancer

Barbara K. Dunn, D. Lawrence Wickerham, Leslie G. Ford

From the National Cancer Institute, Division of Cancer Prevention, Basic Prevention Science Research Group and Deputy Director's Office, Bethesda, MD; and National Surgical Adjuvant Breast and Bowel Project, Allegheny Hospital, Pittsburgh, PA

Address reprint requests to Leslie G. Ford, MD, National Cancer Institute, 6130 Executive Blvd, Room 2046, Bethesda, MD 20892; e-mail: lf50z{at}nih.gov.

Carcinogenesis in the breast is a hormonally dependent process. Evidence implicating estrogen as a key breast carcinogen comes from various lines of investigation. Traditional epidemiologic studies demonstrate associations between estrogen exposure, both exogenous and endogenous, and increased breast cancer risk. Ongoing genetic epidemiologic studies also show associations between specific polymorphisms in estrogen-metabolizing genes and risk, albeit inconsistently. The application of these findings to the treatment and, more recently, the prevention of breast cancer has led to the development of agents that either (1) inhibit estrogen action at the estrogen receptor (selective estrogen receptor modulators (SERMs]); or (2) inhibit estrogen-synthesizing enzymes, thereby abrogating synthesis of this hormone (aromatase inhibitors). Large phase III trials have evaluated the ability of such agents to reduce the incidence of breast cancer in women at increased risk of the disease. The National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1: Breast Cancer Prevention Trial (BCPT) demonstrated the superiority of the SERM tamoxifen to placebo in reducing breast cancer risk, leading to the Food and Drug Administration approval of tamoxifen for risk reduction. The implementation of tamoxifen for this indication has not become widespread in clinical practice, however, for a variety of reasons that we discuss. Results from the NSABP Study of Tamoxifen and Raloxifene, which compares the risk-reducing efficacy as well as toxicity of these two SERMs in a similar high-risk population, will be available in the near future. Based on promising data involving reduction of contralateral breast cancer risk in adjuvant studies, several aromatase inhibitors, including letrozole, anastrozole, and exemestane, are being incorporated into trials evaluating their efficacy as preventive agents in women at increased risk.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Greenwald and B. K. Dunn Landmarks in the History of Cancer Epidemiology Cancer Res., March 15, 2009; 69(6): 2151 - 2162. [Abstract] [Full Text] [PDF]

				R. Shibuya, T. Suzuki, Y. Miki, K. Yoshida, T. Moriya, K. Ono, J.-i. Akahira, T. Ishida, H. Hirakawa, D. B Evans, et al. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast Endocr. Relat. Cancer, March 1, 2008; 15(1): 113 - 124. [Abstract] [Full Text] [PDF]

				M. Fatouros, G. Baltoyiannis, and D. H. Roukos The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations Ann. Surg. Oncol., January 1, 2008; 15(1): 21 - 33. [Abstract] [Full Text] [PDF]

				M. R. Sartippour, R. Pietras, D. C. Marquez-Garban, H.-W. Chen, D. Heber, S. M. Henning, G. Sartippour, L. Zhang, M. Lu, O. Weinberg, et al. The combination of green tea and tamoxifen is effective against breast cancer Carcinogenesis, December 1, 2006; 27(12): 2424 - 2433. [Abstract] [Full Text] [PDF]

				R. Lupu and J. A. Menendez Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators? Endocrinology, September 1, 2006; 147(9): 4056 - 4066. [Abstract] [Full Text] [PDF]

				V. P. Tryndyak, L. Muskhelishvili, O. Kovalchuk, R. Rodriguez-Juarez, B. Montgomery, M. I. Churchwell, S. A. Ross, F. A. Beland, and I. P. Pogribny Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis Carcinogenesis, August 1, 2006; 27(8): 1713 - 1720. [Abstract] [Full Text] [PDF]

				K. Altundag Challenge in the Treatment of Estrogen-Receptor-Negative Ductal Carcinoma in Situ J. Clin. Oncol., July 1, 2005; 23(19): 4469 - 4470. [Full Text] [PDF]